Clinical features of serous retinopathy observed with cobimetinib in patients with BRAF-mutated melanoma treated in the randomized coBRIM study.

Ocular toxicity due to Trametinib and Dabrafenib. BMC Ophthalmol (2017) 0.75

Mutations of the BRAF gene in human cancer. Nature (2002) 65.42

Distinct sets of genetic alterations in melanoma. N Engl J Med (2005) 17.26

Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med (2014) 5.65

Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med (2014) 5.43

Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med (2014) 4.71

Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet (2015) 3.13

Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial. Lancet Oncol (2012) 2.86

Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study. Lancet Oncol (2014) 2.10

Central serous chorioretinopathy: update on pathophysiology and treatment. Surv Ophthalmol (2013) 2.07

The clinical development of MEK inhibitors. Nat Rev Clin Oncol (2014) 1.79

Bilateral subfoveal neurosensory retinal detachment associated with MEK inhibitor use for metastatic cancer. JAMA Ophthalmol (2014) 1.30

The blood-retinal barrier: structure and functional significance. Methods Mol Biol (2011) 1.20

MEK inhibitors: a new class of chemotherapeutic agents with ocular toxicity. Eye (Lond) (2015) 1.18

MEK/ERK pathway mediates UVB-induced AQP1 downregulation and water permeability impairment in human retinal pigment epithelial cells. Int J Mol Med (2009) 1.13

Transient MEK inhibitor-associated retinopathy in metastatic melanoma. Ann Oncol (2014) 1.12

Effect of inhibition of the FGFR-MAPK signaling pathway on the development of ocular toxicities. Cancer Treat Rev (2013) 1.01

Multicenter phase I trial of the mitogen-activated protein kinase 1/2 inhibitor BAY 86-9766 in patients with advanced cancer. Clin Cancer Res (2013) 0.90

Bilateral Multifocal Central Serous-Like Chorioretinopathy due to MEK Inhibition for Metastatic Cutaneous Melanoma. Case Rep Ophthalmol Med (2013) 0.90

Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. Lancet Oncol (2016) 1.05

Immuno-oncology combinations: a review of clinical experience and future prospects. Clin Cancer Res (2014) 0.99

Genetic Variants Related to Longer Telomere Length are Associated with Increased Risk of Renal Cell Carcinoma. Eur Urol (2017) 0.75